ProQuest Investments, founded in 1998, is a healthcare venture capital firm headquartered in Princeton, New Jersey, with additional offices in San Diego and Montreal. The firm manages over $875 million and employs a team of 12 deal professionals who focus on investments in healthcare companies at various stages, from seed to late-stage financing. ProQuest Investments has a diverse portfolio that showcases its commitment to supporting the growth of innovative businesses within the healthcare industry. The firm possesses specialized expertise in therapeutics, particularly in areas such as drug discovery technologies and molecular analysis, addressing significant unmet medical needs. With a proven track record and extensive experience across various therapeutic categories, including oncology, pain, and infectious diseases, ProQuest Investments aims to foster long-term, mutually beneficial partnerships with exceptional entrepreneurs in the healthcare sector.
SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.
ReVision Optics
Venture Round in 2016
ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.
Agile Therapeutics
Post in 2015
Agile Therapeutics is a women's healthcare company dedicated to addressing the unmet health needs of women through the development and commercialization of prescription contraceptive products. The company's lead product, Twirla, is a once-weekly transdermal patch that delivers a combination of levonorgestrel and ethinylestradiol, providing a non-daily contraceptive option. In addition to Twirla, Agile Therapeutics is advancing a pipeline of related products, including various regimens designed to offer customizable menstrual cycle management options, such as AG200-ER for extended cycles and AG200-SP for lighter periods. The firm's proprietary Skinfusion technology facilitates effective drug delivery through the skin. Headquartered in Princeton, New Jersey, Agile Therapeutics aims to enhance women's reproductive health by providing innovative contraceptive solutions.
SomaLogic
Venture Round in 2014
SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.
Mevion Medical Systems
Private Equity Round in 2014
Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.
Telormedix
Series B in 2013
Telormedix is a biopharmaceutical company specializing in the development of targeted therapies that harness the innate immune system to treat cancer and autoimmune diseases. The company focuses on creating innovative drug formulations based on a clinically active small molecule compound, which has a recognized safety profile and is aimed at specific immunotherapeutic targets. This approach is designed to enhance treatment options for cancer patients, ultimately leading to improved medical outcomes. Telormedix aims to advance the field of immunotherapy by delivering effective solutions for both cancer and infectious diseases.
Immune Design
Series C in 2013
Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.
ReVision Optics
Series E in 2013
ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.
Mevion Medical Systems
Private Equity Round in 2013
Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.
ReVision Optics
Series E in 2013
ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.
Mersana Therapeutics
Series A in 2012
Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.
Agile Therapeutics
Series C in 2012
Agile Therapeutics is a women's healthcare company dedicated to addressing the unmet health needs of women through the development and commercialization of prescription contraceptive products. The company's lead product, Twirla, is a once-weekly transdermal patch that delivers a combination of levonorgestrel and ethinylestradiol, providing a non-daily contraceptive option. In addition to Twirla, Agile Therapeutics is advancing a pipeline of related products, including various regimens designed to offer customizable menstrual cycle management options, such as AG200-ER for extended cycles and AG200-SP for lighter periods. The firm's proprietary Skinfusion technology facilitates effective drug delivery through the skin. Headquartered in Princeton, New Jersey, Agile Therapeutics aims to enhance women's reproductive health by providing innovative contraceptive solutions.
Telormedix
Series B in 2012
Telormedix is a biopharmaceutical company specializing in the development of targeted therapies that harness the innate immune system to treat cancer and autoimmune diseases. The company focuses on creating innovative drug formulations based on a clinically active small molecule compound, which has a recognized safety profile and is aimed at specific immunotherapeutic targets. This approach is designed to enhance treatment options for cancer patients, ultimately leading to improved medical outcomes. Telormedix aims to advance the field of immunotherapy by delivering effective solutions for both cancer and infectious diseases.
Mevion Medical Systems
Venture Round in 2012
Mevion Medical Systems, Inc. is a developer of proton therapy systems aimed at enhancing cancer treatment worldwide. Founded in 2004 and headquartered in Littleton, Massachusetts, with additional offices in the United Kingdom, China, and Japan, the company has pioneered modern proton therapy technology. Its flagship product, the MEVION S250 Proton Therapy System, is designed to retain the benefits of traditional proton therapy while addressing challenges related to size, cost, and complexity. By integrating advanced patented technology, Mevion aims to improve beam reliability and operational efficiency, ultimately making proton therapy more accessible and economically viable for cancer treatment centers and clinicians globally.
MethylGene
Venture Round in 2011
MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.
Aires Pharmaceuticals
Series B in 2010
Aires Pharmaceuticals, Inc. is a clinical stage pharmaceutical company based in San Diego, California, that focuses on developing therapies for pulmonary disorders. Founded in 2006, the company specializes in creating treatments for conditions such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure. One of its key products is Aironite, an inhaled medication designed to address a range of respiratory issues, including pulmonary hypertension, cystic fibrosis, pneumonia, and other bacterial pulmonary infections. Through its innovative approaches, Aires Pharmaceuticals aims to improve the quality of life for patients suffering from various pulmonary conditions.
Immune Design
Series B in 2010
Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.
ReVision Optics
Series D in 2010
ReVision Optics, Inc. is a company based in Lake Forest, California, specializing in the design, manufacture, and delivery of implantable products aimed at treating presbyopia, a condition that affects near vision due to aging. The company offers the PRESBYLENS Corneal Inlay, a patented refractive surgery solution that enhances near vision for patients experiencing this common age-related vision loss. By providing innovative optical technology, ReVision Optics enables ophthalmology professionals to deliver improved eyesight solutions to their patients. Founded in 1996 and originally named IntraLens Vision, Inc., the company rebranded in 2005 to align with its focus on presbyopia treatments.
Predictive Biosciences
Series C in 2010
Predictive Biosciences, Inc., a molecular diagnostics company, develops diagnostic products for informed cancer management. It specializes in proteomics, diagnostics, oncology, and tumor biomarkers. The company offers biomarkers and proteomics-based assay technologies. These assays detect urinary biomarkers associated with the physiological changes resulting from cancer development and progression. It also provides Triage Monitoring Assay, which allows physicians to delay and invasive diagnostic procedures; Interval Monitoring Assay that is for surveillance and detection of cancer between follow-ups; and Stratification Assay, which supports a physician's decision to manage a patient. Predictive Biosciences, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
Agile Therapeutics
Series B in 2010
Agile Therapeutics is a women's healthcare company dedicated to addressing the unmet health needs of women through the development and commercialization of prescription contraceptive products. The company's lead product, Twirla, is a once-weekly transdermal patch that delivers a combination of levonorgestrel and ethinylestradiol, providing a non-daily contraceptive option. In addition to Twirla, Agile Therapeutics is advancing a pipeline of related products, including various regimens designed to offer customizable menstrual cycle management options, such as AG200-ER for extended cycles and AG200-SP for lighter periods. The firm's proprietary Skinfusion technology facilitates effective drug delivery through the skin. Headquartered in Princeton, New Jersey, Agile Therapeutics aims to enhance women's reproductive health by providing innovative contraceptive solutions.
Adastra Pharmaceuticals
Venture Round in 2010
Adastra Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in developing innovative treatments for cancer. Founded in 2005 and previously known as Tragara Pharmaceuticals, the company is focused on creating proprietary medicines aimed at improving patient care in oncology. Among its key products is an oral multi-kinase inhibitor designed to inhibit critical cyclin-dependent kinases, which may enhance patient survival rates and overall quality of life. Adastra Pharmaceuticals is dedicated to advancing its portfolio of cancer therapies to meet the needs of healthcare professionals and patients alike.
ORTHOCON
Venture Round in 2009
Orthocon is a medical therapeutics company focused on developing innovative absorbable products specifically for orthopedic and spine surgeries. The company's core offering is the HEMASORB Absorbable Bone Hemostat Matrix, which is a ready-to-use, biocompatible, and water-resistant putty designed to effectively stop bone bleeding when applied to damaged or cut bones. Orthocon manufactures, markets, and sells these implantable products, aiming to enhance surgical outcomes and improve patient care in orthopedic procedures.
Gloucester Pharmaceuticals
Series D in 2009
Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing cancer therapeutics, specifically targeting hematological malignancies. Owned by Celgene, the company specializes in acquiring clinical-stage oncology drug candidates and advancing them through regulatory approval and commercialization. Its primary compound, romidepsin, is a late-stage drug candidate classified as a histone deacetylase (HDAC) inhibitor. Romidepsin has demonstrated potential efficacy for various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of several classes of HDACs, thus positioning the company as a significant player in the oncology therapeutic landscape.
Biosyntech
Venture Round in 2009
Biosyntech Inc. is a Canadian company focused on developing biotherapeutic thermogels for tissue repair and the delivery of therapeutic agents. Its technology platform, known as BST-Gel, utilizes hydrogels made from chitosan, a natural biopolymer sourced from crustacean shells. The company's leading products currently in clinical trials include BST-CarGel for cartilage repair, BST-DermOn for wound healing, and BST-InPod, which aims to treat chronic pain associated with plantar fat pad atrophy in the heel and forefoot. Additionally, Biosyntech is involved in clinical studies for BST-InPod in collaboration with Nicholas Piramal India, Ltd. The company, incorporated in 1994, is headquartered in Laval, Canada.
Zosano Pharma
Series B in 2009
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company headquartered in Fremont, California, established in 2006. The company specializes in developing innovative drug delivery technologies aimed at addressing unmet medical needs. Its primary focus is on providing therapeutics for migraine sufferers through its proprietary intracutaneous microneedle system, which facilitates rapid systemic administration and absorption of medications. Zosano's lead product candidate, Qtrypta (M207), is a formulation of zolmitriptan designed to offer an improved pharmacokinetic profile compared to traditional dosage forms. By leveraging its advanced delivery system, Zosano Pharma aims to enhance patient outcomes and expand the potential for commercialization of its therapeutic products.
Clovis Oncology
Venture Round in 2009
Clovis Oncology, Inc. is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of anti-cancer agents in the United States, Europe, and other international markets. The company is known for its product Rubraca (rucaparib), an oral small molecule inhibitor designed to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Additionally, Clovis is developing lucitanib, an oral inhibitor that targets various tyrosine kinase receptors associated with tumor growth. The company utilizes precision medicine and companion diagnostics to ensure that therapies are directed toward patients most likely to benefit from them. Clovis Oncology distributes its products primarily through specialty distributors and pharmacy providers. Founded in 2009 and headquartered in Boulder, Colorado, the company has established partnerships and licensing agreements with multiple pharmaceutical organizations, enhancing its ability to innovate within the oncology sector.
ORTHOCON
Series B in 2009
Orthocon is a medical therapeutics company focused on developing innovative absorbable products specifically for orthopedic and spine surgeries. The company's core offering is the HEMASORB Absorbable Bone Hemostat Matrix, which is a ready-to-use, biocompatible, and water-resistant putty designed to effectively stop bone bleeding when applied to damaged or cut bones. Orthocon manufactures, markets, and sells these implantable products, aiming to enhance surgical outcomes and improve patient care in orthopedic procedures.
Aerovance
Venture Round in 2009
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.
Telormedix
Series A in 2008
Telormedix is a biopharmaceutical company specializing in the development of targeted therapies that harness the innate immune system to treat cancer and autoimmune diseases. The company focuses on creating innovative drug formulations based on a clinically active small molecule compound, which has a recognized safety profile and is aimed at specific immunotherapeutic targets. This approach is designed to enhance treatment options for cancer patients, ultimately leading to improved medical outcomes. Telormedix aims to advance the field of immunotherapy by delivering effective solutions for both cancer and infectious diseases.
Gemin X Pharmaceuticals
Series C in 2008
Gemin X Pharmaceuticals focuses on the discovery, development, and commercialization of innovative cancer therapeutics aimed at enhancing patient outcomes. The company's research has centered on the Bcl-2 cell death regulation pathway, leading to the development of GX15-070 (obatoclax), a small molecule designed to selectively trigger programmed cell death, or apoptosis, and potentially induce cancer cell autophagy. Obatoclax has demonstrated promising results in preclinical and early clinical trials and is currently undergoing Phase 2 clinical trials as both a standalone treatment and in combination with other therapies. Additionally, Gemin X is involved in developing other oncology products, including GMX1777, which inhibits NAD+ synthesis. The patent for obatoclax is secured until 2025, reinforcing the company's commitment to advancing cancer treatment options.
Sopherion Therapeutics
Venture Round in 2008
Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.
Excaliard Pharmaceuticals
Series A in 2007
Excaliard Pharmaceuticals is a biotechnology company that specializes in the development and commercialization of antisense drugs aimed at treating scarring and other fibrotic diseases. The firm focuses on creating targeted therapeutics that address dermatological disorders, providing innovative solutions for patients suffering from various skin conditions. By employing advanced antisense technology, Excaliard aims to improve treatment outcomes for individuals with fibrotic diseases, enhancing their quality of life through effective localized therapies.
Zosano Pharma
Series A in 2007
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company headquartered in Fremont, California, established in 2006. The company specializes in developing innovative drug delivery technologies aimed at addressing unmet medical needs. Its primary focus is on providing therapeutics for migraine sufferers through its proprietary intracutaneous microneedle system, which facilitates rapid systemic administration and absorption of medications. Zosano's lead product candidate, Qtrypta (M207), is a formulation of zolmitriptan designed to offer an improved pharmacokinetic profile compared to traditional dosage forms. By leveraging its advanced delivery system, Zosano Pharma aims to enhance patient outcomes and expand the potential for commercialization of its therapeutic products.
LEAD Therapeutics
Series A in 2007
LEAD Therapeutics, Inc. is a chemistry-driven drug discovery company focused on delivering novel and differentiated small molecule IND candidates against clinically validated therapeutic targets, focused primarily on the treatment of Cancer and infectious diseases.
5asec
Acquisition in 2007
5asec is a textile care brand that provides its customers with dry cleaning and laundry services. 5asec provides its services in 3 segments, including basic services: dry cleaning, professional washing and steam ironing, and stain cleaning; professional services: duvet and home linen treatment, alterations services; and carpets, furniture, and leather cleaning; and textile care solutions: maxima treatment, appret finish, anti-moth and dust mites’ repellent solutions, and water repellent treatments. 5asec is headquartered in Geneva, Switzerland.
Adastra Pharmaceuticals
Series A in 2007
Adastra Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in developing innovative treatments for cancer. Founded in 2005 and previously known as Tragara Pharmaceuticals, the company is focused on creating proprietary medicines aimed at improving patient care in oncology. Among its key products is an oral multi-kinase inhibitor designed to inhibit critical cyclin-dependent kinases, which may enhance patient survival rates and overall quality of life. Adastra Pharmaceuticals is dedicated to advancing its portfolio of cancer therapies to meet the needs of healthcare professionals and patients alike.
Alaunos Therapeutics
Post in 2007
Alaunos Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer, specifically through adoptive TCR-T cell therapy. The company utilizes a unique gene expression and control technology to deliver DNA that targets neoantigens derived from genomic mutations in solid tumors. This approach aims to enhance the immune response against cancer cells. Alaunos is currently conducting Phase 2 clinical studies to evaluate the efficacy of its therapies, including the immune system cytokine interleukin-12 for breast cancer and advanced melanoma. Additionally, the company is exploring multiple investigational new drug applications for new therapeutic targets, leveraging its advanced technology to improve treatment outcomes for patients.
NovaDel Pharma
Venture Round in 2006
NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary oral spray technology delivery system offers the patient the potential for (i) more rapid delivery of drugs to the bloodstream allowing for quicker onset of therapeutic effects compared to conventional oral dosage forms; (ii) increased bioavailability of a drug by avoiding metabolism by the liver; (iii) improved drug safety profile by reducing the required dosage, including possible reduction of side effects; (iv) improved dosage reliability; (v) allowing medication to be taken without water; (vi) avoiding the need to swallow as is the case with many medications; and (vii) improved patient convenience and compliance. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies.
Cabrellis Pharmaceuticals
Series A in 2006
Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.
Alaunos Therapeutics
Post in 2006
Alaunos Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer, specifically through adoptive TCR-T cell therapy. The company utilizes a unique gene expression and control technology to deliver DNA that targets neoantigens derived from genomic mutations in solid tumors. This approach aims to enhance the immune response against cancer cells. Alaunos is currently conducting Phase 2 clinical studies to evaluate the efficacy of its therapies, including the immune system cytokine interleukin-12 for breast cancer and advanced melanoma. Additionally, the company is exploring multiple investigational new drug applications for new therapeutic targets, leveraging its advanced technology to improve treatment outcomes for patients.
Optimer Pharmaceuticals
Series D in 2005
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of anti-infective products. The company primarily focuses on addressing gastrointestinal infections and related diseases that have limited treatment options. Its notable late-stage product candidates include fidaxomicin, an antibacterial drug designed for the treatment of Clostridium difficile-associated diarrhea, and Pruvel (prulifloxacin). In addition to these, Optimer's portfolio comprises CEM-101, OPT-822/OPT-821 combination therapy, and OPT-88. The company aims to create therapies that significantly improve patient outcomes and alleviate the burden of infectious diseases.
Mersana Therapeutics
Venture Round in 2005
Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.
Guava Technologies
Series E in 2005
Guava Technologies, Inc. is a manufacturer of biotechnology and medical devices, specializing in the development and design of products for life science research and clinical diagnostics. The company provides a range of solutions, including flow cytometry systems and assays for cell counting, viability, antibody quantification, apoptosis, and cytotoxicity. These products support various applications in cell biology research and drug discovery, with a particular emphasis on HIV/AIDS monitoring. Founded in 1998 and headquartered in Hayward, California, Guava Technologies operates as a subsidiary of Millipore Corp.
EUSA Pharma
Venture Round in 2005
EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.
Gloucester Pharmaceuticals
Series B in 2004
Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing cancer therapeutics, specifically targeting hematological malignancies. Owned by Celgene, the company specializes in acquiring clinical-stage oncology drug candidates and advancing them through regulatory approval and commercialization. Its primary compound, romidepsin, is a late-stage drug candidate classified as a histone deacetylase (HDAC) inhibitor. Romidepsin has demonstrated potential efficacy for various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of several classes of HDACs, thus positioning the company as a significant player in the oncology therapeutic landscape.
BioRexis
Series B in 2004
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
Threshold Pharmaceuticals
Series B in 2004
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.
Novacea
Series C in 2004
As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.
Conforma Therapeutics
Series C in 2003
Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California
Sopherion Therapeutics
Series A in 2003
Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.
Iomai
Series C in 2003
Iomai Corporation specializes in the discovery and development of vaccines and immune system stimulants using a unique, needle-free approach known as transcutaneous immunization (TCI). This technology utilizes antigen-presenting cells located in the outer layers of the skin to enhance immune responses, allowing for the improvement of existing vaccines and the creation of new ones that can only be administered through this method. Founded in 1997 and based in Gaithersburg, Maryland, Iomai aims to expand the global vaccine market. Following its acquisition by Intercell Ag, the company was rebranded as Intercell USA, Inc. and now operates as a subsidiary of Intercell Biomedical Research & Development AG.
BioRexis
Series A in 2002
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
Novacea
Series B in 2002
As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.
Pharmion
Venture Round in 2002
Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.
Threshold Pharmaceuticals
Series A in 2002
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.
Salmedix
Series B in 2002
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
Optimer Pharmaceuticals
Series B in 2001
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of anti-infective products. The company primarily focuses on addressing gastrointestinal infections and related diseases that have limited treatment options. Its notable late-stage product candidates include fidaxomicin, an antibacterial drug designed for the treatment of Clostridium difficile-associated diarrhea, and Pruvel (prulifloxacin). In addition to these, Optimer's portfolio comprises CEM-101, OPT-822/OPT-821 combination therapy, and OPT-88. The company aims to create therapies that significantly improve patient outcomes and alleviate the burden of infectious diseases.
Guava Technologies
Series B in 2001
Guava Technologies, Inc. is a manufacturer of biotechnology and medical devices, specializing in the development and design of products for life science research and clinical diagnostics. The company provides a range of solutions, including flow cytometry systems and assays for cell counting, viability, antibody quantification, apoptosis, and cytotoxicity. These products support various applications in cell biology research and drug discovery, with a particular emphasis on HIV/AIDS monitoring. Founded in 1998 and headquartered in Hayward, California, Guava Technologies operates as a subsidiary of Millipore Corp.
Acurian
Series A in 1998
Acurian provides solutions needed to recruit, enroll, and retain patients for clinical trials. The company offers recruitment feasibility, site identification and selection, patient recruitment and retention, and cancer solutions. Acurian was founded in 1998 and is based in Horsham, Pennsylvania.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.